Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia. (9th January 2022)

• Record Type: Journal Article
• Authors: Huang, Pei; Li, Yuan-Yuan; Park, Jung E.; Huang, Ping; Xiao, Qin; Wang, Ying; Chen, Sheng; Chen, Sheng-Di; Liu, Jun; Wu, Yi-Wen
• Is Part Of: Canadian journal of neurological sciences. Volume 49:Number 1(2022)
• Page Start: 123
• Page End: 128
• Publication Date: 2022-01-09
• Subjects: Parkinson's disease -- Foot dystonia -- Botulinum toxin A -- Gait; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Electronic journals; 616.8
• DOI: 10.1017/cjn.2021.42
• Languages: English
• ISSNs: 0317-1671

Abstract

ABSTRACT: We investigated the effects of botulinum toxin on gait in Parkinson's disease (PD) patients with foot dystonia. Six patients underwent onabotulinum toxin A injection and were assessed by Burke–Fahn–Marsden Dystonia Rating Scale (BFMDRS), visual analog scale (VAS) of pain, Timed Up and Go (TUG), Berg Balance Test (BBT), and 3D gait analysis at baseline, 1 month, and 3 months. BFMDRS (p = 0.002), VAS (p = 0.024), TUG (p = 0.028), and BBT (p = 0.034) were improved. Foot pressures at Toe 1 (p = 0.028) and Midfoot (p = 0.018) were reduced, indicating botulinum toxin's effects in alleviating the dystonia severity and pain and improving foot pressures during walking in PD.